UCLA Health and the Department of Urology at UCLA have created a new telehealth cancer genetics program that will provide rapid access to high-quality genetic counseling and testing.
University of Michigan Rogel Cancer Center researchers received a $2 million grant from NCI to prepare the next generation of scientists focused on cancer care delivery.
Memorial Sloan Kettering and Hackensack Meridian Health have formed an Immunology Research Collaboration as part of their partnership. Through this joint initiative, researchers can apply for funding to support immunotherapy research.
Ashion Analytics, a clinical laboratory of the Translational Genomics Research Institute, an affiliate of City of Hope, is now part of NCI's MATCH program, which provides patients who have rare or difficult-to-treat cancers with access to unique clinical trials nationwide that might give them the best therapeutic treatments and outcomes.
A new approach to better select breast cancer patients in need of urgent surgery or chemotherapy during the COVID-19 pandemic has been developed by researchers at The Royal Marsden and the Breast Cancer Now Research Centre at The Institute of Cancer Research, London, in collaboration with colleagues in the U.K., Germany, and the U.S.
ChristianaCare has developed a virtual telehealth service that provides daily monitoring of employees for COVID-19 symptoms, testing, and care for employees who test positive.
A total of 1,066 patients have joined a HealthTree observational study on COVID-19 and multiple myeloma. All participating patients have filled out a HealthTree profile by contributing their de-identified health data and answered survey questions related to their outcomes during the COVID-19 pandemic.
As we approach the middle of June, Georgia appears to have come to the other side of its COVID-19 curve. Available information from the Georgia Department of Health reveals Georgia has nearly 54,000 confirmed COVID-19 cases, with the heaviest concentration of cases in the metro Atlanta area (as a result of population size, not density).
Fajgenbaum gained insight into COVID-19 while seeking treatment for Castleman disease (which he has)
David C. Fajgenbaum knows all about facing the unknown.
“It just dawned upon us, ‘Hey, we know how to block inflammation,’” recalls Louis Staudt, chief of NCI’s Lymphoid Malignancies Branch and director of the Center for Cancer Genomics.
